How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
How to Select a CMO: Part 2
Ensuring Industry Compliance in Identifying Genotoxic Impurities in APIs
Making the Right Connections inside Massachusetts for Business Development
From Molecule Discovery to Commercialization: Why it’s Good to Have One CDMO for the Entire Journe...
Why Drug Master Files Are An Important Part of API Manufacturing
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...
